HERNDON, VA, October 12, 2023 – Exostar, the leader in trusted, secure business collaboration for highly regulated industries including life sciences, will participate in the 6th annual Summit for Clinical Ops Executives (SCOPE) Europe conference. The SCOPE Europe 2023 event, “Decentralization and Digitalization of Clinical Trials,” takes place October 17-18 in Barcelona.
On October 17 at 4:20pm local time, Exostar will present, “Speed to Access – Simplifying Study Start-Up for All Clinical Users,” as part of the Feasibility, Site Selection and Study Activation track. Attendees will learn about innovative strategies to empower sponsors to streamline study start-up processes, enhance the clinical site experience, and eliminate the technology burden that often hinders research efficiency. The session will feature practical solutions that drive smoother operations, improve collaboration, and accelerate the timeline for bringing new drugs to market.
Exostar’s presentation draws from its experience as the leading provider of identity and access management (IAM) solutions for the clinical trials community. That community currently consists of half of the 20 largest global pharmaceutical firms, over 20 thousand sponsor partner organizations encompassing greater than 30 thousand clinical sites, and more than 650 thousand users spanning 130+ countries worldwide.
Secure Access Manager (SAM), Exostar’s IAM product that resides within The Exostar Platform’s Secure Access module, serves as a neutral identity provider delivering trusted identities. It speeds study start-up and partner onboarding for sponsors and eliminates the need for site personnel to maintain unique login credentials for each application they access in support of clinical studies.
With more than 100 connected applications spanning CTMS (Clinical Trial Management System), LMS (Learning Management System), EDC (Electronic Data Capture), Payments, Lab, IRT (Interactive Response Technology), and eCOA (Electronic Clinical Outcome Assessment) categories, SAM gives site users single sign-on access with no fees to all the systems to which they have been granted permission by the asset owners. The process to issue login credentials for each individual site user takes upwards of 50 minutes for as few as 7 applications (and longer for more) yet requires as little as 1 minute with SAM – allowing site users to get to work immediately without worrying about subsequently maintaining dozens of passwords for application access. SAM stands as a proven product used for thousands of studies to date.
“For the past decade, life sciences sponsors and their partners have relied on SAM to promote trusted, efficient collaboration as they execute clinical studies,” said Tony Farinaro, Exostar’s Chief Revenue Officer. “Our life sciences community continues to grow rapidly because SAM offers a track record of success with clear, compelling benefits to all parties, and, quite simply, it works.”
For those attending SCOPE Europe 2023 who wish to learn more about Exostar’s presentation or SAM, stop by Stand #11.
The Exostar Platform supports exclusive communities within highly regulated industries where organizations securely collaborate, share information, and operate compliantly. Within these communities, we build trust. Nearly 200,000 companies and agencies in 175 countries trust Exostar to strengthen security, reduce expenditures, raise productivity, and help them achieve their digital transformation initiatives. Nearly half of the Defense Industrial Base, including 98 of the top 100, transact business over The Exostar Platform. Ten of the top twenty global biopharmaceutical companies rely on The Exostar Platform to help them speed new medicines and therapies to market. Exostar is a Gartner Cool Vendor. For more information, please visit www.exostar.com, and follow Exostar on LinkedIn and Twitter.
(703) 793-7735 (o)
(703) 624-4675 (m)